deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03828292

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Japanese Participants With Relapsed/Refractory Multiple Myeloma

Sponsor: GlaxoSmithKline

Conditions Multiple Myeloma
Interventions Belantamab mafodotin Bortezomib Dexamethasone Pomalidomide
Updated 18 times since 2019 Last updated: Aug 1, 2025 Started: Mar 14, 2019 Primary completion: Apr 6, 2023 Completion: Sep 5, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 18 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Dec 2023 · 21 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. May 2025 — Sep 2025 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 13 earlier versions

  1. Mar 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  3. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  5. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  6. Mar 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Jan 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  10. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  11. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  12. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Mar 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations